Immunic Analyst Ratings
Immunic Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/10/2023 | 278.38% | Wedbush | $5 → $7 | Maintains | Outperform |
| 07/27/2023 | 170.27% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 01/31/2023 | 170.27% | Wedbush | → $5 | Assumes | → Outperform |
| 10/21/2022 | 170.27% | SVB Leerink | $9 → $5 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1305.41% | HC Wainwright & Co. | → $26 | Assumes | → Buy |
| 08/08/2022 | 1791.89% | Aegis Capital | $40 → $35 | Maintains | Buy |
| 06/03/2022 | 386.49% | SVB Leerink | $45 → $9 | Maintains | Outperform |
| 05/18/2022 | 2008.11% | Piper Sandler | $71 → $39 | Maintains | Overweight |
| 09/07/2021 | 1251.35% | HC Wainwright & Co. | $40 → $25 | Maintains | Buy |
| 04/15/2021 | 2872.97% | Aegis Capital | → $55 | Initiates Coverage On | → Buy |
| 03/24/2021 | 2872.97% | JMP Securities | → $55 | Initiates Coverage On | → Market Outperform |
| 10/02/2020 | 2332.43% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 08/26/2020 | 3737.84% | Piper Sandler | → $71 | Initiates Coverage On | → Overweight |
| 08/21/2020 | 2927.03% | HC Wainwright & Co. | $60 → $56 | Maintains | Buy |
| 08/03/2020 | 3143.24% | HC Wainwright & Co. | $45 → $60 | Maintains | Buy |
| 07/20/2020 | 2062.16% | BMO Capital | → $40 | Initiates Coverage On | → Outperform |
| 06/05/2020 | 3089.19% | Wedbush | → $59 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 2332.43% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 08/12/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 07/11/2019 | 2062.16% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2023 年 10 月 10 日 | 278.38% | Wedbush | 5 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 07/27/2023 | 170.27% | Wedbush | → 5 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 01/31/2023 | 170.27% | Wedbush | → 5 美元 | 假设 | → 跑赢大盘 |
| 10/21/2022 | 170.27% | SVB Leerink | 9 美元 → 5 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 09/19/2022 | 1305.41% | HC Wainwright & Co. | → 26 美元 | 假设 | → 购买 |
| 08/08/2022 | 1791.89% | 宙斯盾资本 | 40 美元 → 35 美元 | 维护 | 购买 |
| 06/03/2022 | 386.49% | SVB Leerink | 45 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 05/18/2022 | 2008.11% | 派珀·桑德勒 | 71 美元 → 39 美元 | 维护 | 超重 |
| 09/07/2021 | 1251.35% | HC Wainwright & Co. | 40 美元 → 25 美元 | 维护 | 购买 |
| 2021 年 4 月 15 日 | 2872.97% | 宙斯盾资本 | → 55 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 3 月 24 日 | 2872.97% | JMP 证券 | → 55 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
| 2020 年 2 月 10 日 | 2332.43% | SVB Leerink | → 45 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 08/26/2020 | 3737.84% | 派珀·桑德勒 | → 71 美元 | 启动覆盖范围开启 | → 超重 |
| 08/21/2020 | 2927.03% | HC Wainwright & Co. | 60 美元 → 56 美元 | 维护 | 购买 |
| 2020 年 3 月 8 日 | 3143.24% | HC Wainwright & Co. | 45 美元 → 60 美元 | 维护 | 购买 |
| 2020 年 7 月 20 日 | 2062.16% | BMO Capital | → 40 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 5 月 6 日 | 3089.19% | Wedbush | → 59 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 05/11/2020 | 2332.43% | HC Wainwright & Co. | → 45 美元 | 启动覆盖范围开启 | → 购买 |
| 08/12/2019 | 2062.16% | 查丹资本 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 11 月 7 日 | 2062.16% | 查丹资本 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Immunic (IMUX)?
Immunic (IMUX) 的目标价格是多少？
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on October 10, 2023. The analyst firm set a price target for $7.00 expecting IMUX to rise to within 12 months (a possible 278.38% upside). 4 analyst firms have reported ratings in the last year.
Wedbush于2023年10月10日公布了Immunic（纳斯达克股票代码：IMUX）的最新目标股价。该分析公司将目标股价定为7.00美元，预计IMUX将在12个月内上涨至278.38％（可能上涨278.38％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Immunic (IMUX)?
分析师对Immunic（IMUX）的最新评级是多少？
The latest analyst rating for Immunic (NASDAQ: IMUX) was provided by Wedbush, and Immunic maintained their outperform rating.
Wedbush对Immunic（纳斯达克股票代码：IMUX）的最新分析师评级由Wedbush提供，Immunic维持其跑赢大盘评级。
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Immunic（IMUX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Immunic的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Immunic的最后一次评级是在2023年10月10日提交的，因此你应该预计下一个评级将在2024年10月10日左右公布。
Is the Analyst Rating Immunic (IMUX) correct?
分析师评级 Immunic (IMUX) 是否正确？
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $5.00 to $7.00. The current price Immunic (IMUX) is trading at is $1.85, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Immunic（IMUX）评级保持不变，目标股价为5.00美元至7.00美元。Immunic（IMUX）的当前交易价格为1.85美元，超出了分析师的预测区间。